上皮性卵巢肿瘤组织中PSMD10、Ki67的表达及其临床病理意义

doi:10.11904/j.issn.1002-3070.2017.02.004

摘要/Abstract

摘要： 目的研究上皮性卵巢肿瘤组织中PSMD10和Ki67的表达及其临床病理意义。方法通过免疫组化SP法检测21例卵巢良性肿瘤、31例卵巢交界性肿瘤、156例卵巢癌组织中PSMD10和Ki67的表达情况。结果 PSMD10和Ki67在卵巢癌组织中的阳性表达率显著高于卵巢交界性肿瘤和良性肿瘤(P＜0.05)。PSMD10在卵巢癌组织中的阳性表达率与患者的年龄、病理类型无统计学意义(P＞0.05),而与临床分期、病理分级和残留肿瘤直径有统计学意义(P＜0.05)。卵巢癌组织中PSMD10和Ki67的表达呈正相关(P＜0.01)。结论 PSMD10和Ki67在上皮性卵巢癌的发生、发展中起到了重要的协同作用,可作为判断卵巢癌恶性程度、病情进展的重要指标,联合检测用于指导临床诊断。

关键词: 卵巢癌, PSMD10, Ki67, 免疫组化

Abstract: Objective The objective of this study was to investigate the expression of PSMD10 and Ki67 in epithelial ovarian tumors and its clinicopathological significance.Methods Immunohistochemical method was used to detect the expression of PSMD10 and Ki67 in 21 cases of ovarian benign tumor,31 cases of ovarian borderline tumor and 156 cases of ovarian cancer.Results The positive expression rate of PSMD10 and Ki67 in ovarian cancer was significantly higher than those of ovarian borderline and benign tumor(P＜0.05).The positive expression rate of PSMD10 in ovarian cancer tissues was not different from others groups(P＞0.05).There was significant different the positive expression rate of PSMD10 from clinical stage,pathological grade and residual tumor diameter(P＜0.05).There was a positive correlation between the expression of PSMD10 and Ki67 in ovarian cancer(P＜0.01).Conclusion PSMD10 and Ki67 play an important synergistic role in the carcinogenesis and progression of epithelial ovarian cancer.It can be used as an important index to judge the degree of malignancy and progression of ovarian cancer.Joint testing PSMD10 and Ki67 are used to guide the clinical diagnosis.

Key words: Ovarian cancer, PSMD10, Ki67, Immunohistochemistry

中图分类号:

R737.31

于歌, 孙佳宁, 冯晓玲. 上皮性卵巢肿瘤组织中PSMD10、Ki67的表达及其临床病理意义[J]. 实用肿瘤学杂志, 2017, 31(2): 112-116.

YU Ge,SUN Jianing,FENG Xiaoling. Expression of PSMD10 and Ki67 in epithelial ovarian carcinoma and its clinicopathological significance[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 112-116.

参考文献

1 Saini U,Naidu S,ElNaggar AC,et al.Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis:a potential therapeutic target[J].Oncogene,2016,197(10):1038-1047.
2 Zhang LL,Xu YL,Tang ZH,et al.Effects of alisol B 23-acetate on ovarian cancer cells:G1 phase cell cycle arrest,apoptosis,migration and invasion inhibition[J].Phytomedicine,2016,23(8):800-809.
3 Nishida N,Murakami F,Higaki K.Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer[J].Pathol Int,2016,66(6):337-342.
4 Zeggai S,Harir N,Tou A,et al.Immunohistochemistry and scoring of Ki-67 proliferative index and p53 expression in gastric B cell lymphoma from Northern African population:a pilot study[J].Gastrointest Oncol,2016,7(3):462-468.
5 Dmitrenko AP.Lateral differences in Ki-67 in breast cancer[J].Mol Clin Oncol,2016,4(6):1041-1044.
6 Alves AV,Ribeiro DR,Lima SO,et al.Expression of Ki-67 and P16 INK4a in chemically-induced perioral squamous cell carcinomas in mice[J].Rev Col Bras Cir,2016,43(2):72-79.
7 Himani B,Meera S,Abhimanyu S,et al.Ki-67 immunostaining and its correlation with microvessel density in patients with mutiple myeloma[J].Asian Pac J Cancer Prev,2016,17(5):2559-2564.
8 Soleimani M,Mirmohammad-Sadeghi H,Sadeghi-Aliabadi H,et al.Expression and purification of toxic anti-breast cancer p28-NRC chimeric protein[J].Adv Biomed Res,2016,19(5):70-88.
9 Lulla RR,Goldman S,Yamada T,et al.Phase 1 trial of p28(NSC745104),a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors:A Pediatric Brain Tumor Consortium Study[J].Neuro Oncol,2016,18(8):1319-1325.
10 Uddin MH,Choi MH,Kim WH,et al.Involvement of PSMD10,CDK4,and tumor suppressors in development of intrahepatic cholangiocarcinoma of syrian golden hamsters induced by clonorchis sinensis and n-nitrosodimethylamine[J].PLoS Negl Trop Dis,2015,9(8):e0004008.
11 Chen BF,Suen YK,Gu S,et al.A miR-199a/miR-214 self-regulatory network via PSMD10,TP53 and DNMT1 in testicular germ cell tumor[J].Sci Rep,2014,18(4):6413-6420.
12 Siegel RL,Miller KD,Jemal A.Cancer statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.
13 Kurman RJ,Shih M.The origin and pathogenesis of epithelial ovarian cancer:a proposed unifying theory[J].Am J Surg Pathol,2010,34(3):433-443.
14 Cooke SL,Brenton JD.Evolution of platinum resistance in high-grade serous ovarian cancer[J].Lancet Oncol,2011,12(12):1169-1174.
15 Li J,Tian F,Li D,et al.MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression[J].FEBS Lett,2014,588(18):3491-3500.
16 Higashitsuji H,Itoh K,Nagao T,et al.Reduced stability of retinoblastoma protein by gankyrin,an oncogenic ankyrin-repeat protein overexpressed in hepatomas[J].Nature Medicine,2000,6(1):96-99.
17 Higashitsuji H,Itoh K,Sakurai T,et al.The oncoprotein gankyrin binds to MDM2/HDM2,enhancing ubiquitylation and degradation of p53[J].Cancer Cell,2005,8(1):75-87.
18 Man JH,Liang B,Gu YX,et al.Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells[J].The Journal of Clinical Investigation,2010,120(8):2829-2841.
19 Zhang J,Yang Y,Zhang Z,et al.Gankyrin plays an essential role in estrogen-driven and GPR30-mediated endometrial carcinoma cell proliferation via the PTEN/PI3K/AKT signaling pathway[J].Cancer Letters,2013,339(2):279-287.

[1]	吕博文, 钱钧, 王杰, 钱景荣, 卢莹莹, 苏丽菊, 杨桐树, 李文辉. miR-455-5p在上皮性卵巢癌中表达研究及其靶基因功能分析[J]. 实用肿瘤学杂志, 2019, 33(2): 115-121.
[2]	宋玲, 付琼. 紫云英苷通过抑制HIF-1α诱导的糖酵解途径发挥抗卵巢肿细胞作用的研究[J]. 实用肿瘤学杂志, 2018, 32(6): 503-509.
[3]	姜亮亮综述, 王晶审校. 上皮性卵巢癌远处转移的诊治进展[J]. 实用肿瘤学杂志, 2018, 32(5): 480-482.
[4]	梁冠盈, 迟秋君, 李晓梅. 伏立诺他对卵巢癌SKOV3细胞增殖和凋亡的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(4): 298-302.
[5]	李文辉, 吕博文, 钱钧, 苏丽菊, 杨桐树, 钱景荣, 王杰. MicroRNA-150对上皮性卵巢癌细胞增殖、凋亡和侵袭转移能力的影响[J]. 实用肿瘤学杂志, 2018, 32(3): 208-213.
[6]	毕琦玲, 周立红, 韩毅敏. HOX基因与妇科肿瘤的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 140-143.
[7]	张云艳, 刘亚琴, 王磊, 张琳, 成海燕, 杨姗姗. RIZ1蛋白表达与宫颈鳞状细胞癌临床病理参数及放疗敏感性的相关性研究[J]. 实用肿瘤学杂志, 2017, 31(5): 405-410.
[8]	陈丹, 李加桩, 隋红. 阿帕替尼多重癌1例附文献回顾[J]. 实用肿瘤学杂志, 2017, 31(5): 441-443.
[9]	柴静波, 李萍, 裴志萍. 番茄红素对荷卵巢癌大鼠免疫功能的影响及其机制研究[J]. 实用肿瘤学杂志, 2017, 31(1): 13-17.
[10]	毛维, 陈青娟, 司小敏, 张消, 蒋成. 分泌超高血清AFP胃肝样腺癌1例并文献复习[J]. 实用肿瘤学杂志, 2017, 31(1): 39-42.
[11]	余东阳,刘梓良,韩丽蓉. 58例晚期卵巢癌患者发生腹腔内转移后的临床特征、疗效及预后影响因素分析[J]. 实用肿瘤学杂志, 2016, 30(4): 321-326.
[12]	邓燕红,乐秀,高文超. 抗癌新药NSC319726对卵巢癌基因表达影响的研究[J]. 实用肿瘤学杂志, 2016, 30(4): 332-338.
[13]	郭爽, 刘端阳, 李静, 李佳德, 金晓明. 癌性腹水对卵巢癌细胞增殖及迁移的影响[J]. 实用肿瘤学杂志, 2016, 30(1): 36-40.
[14]	王小霞, 杨明, 张艳桥. SPARC蛋白在胃癌中的表达及与胃癌预后的关系[J]. 实用肿瘤学杂志, 2015, 29(6): 501-506.
[15]	刘静蕾, 姜季, 张明岩, 王影, 尤艳, 王艳. OLC1在结直肠癌中的表达及对预后影响的研究[J]. 实用肿瘤学杂志, 2015, 29(5): 390-394.